https://scholars.lib.ntu.edu.tw/handle/123456789/634648
標題: | Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations: a plain language summary | 作者: | CHIH-HSIN YANG | 關鍵字: | EGFR mutation; afatinib; lay summary; non-small-cell lung cancer; plain language summary | 公開日期: | 二月-2023 | 卷: | 19 | 期: | 4 | 來源出版物: | Future oncology (London, England) | 摘要: | EGFR is a protein on cells that helps control their growth and division. Mutations in the gene for EGFR can cause cancer, including some cases of non-small-cell lung cancer (NSCLC). Afatinib is a medicine that blocks mutated EGFR and helps kill cancer cells. Many different types of EGFR mutation have been identified in people with NSCLC. Over three quarters of cases are caused by two types of EGFR mutation, known as common EGFR mutations, but some cases are caused by unusual/uncommon EGFR mutations. People with NSCLC who have these unusual/ uncommon EGFR mutations are often excluded from clinical trials. Consequently, researchers don't really know how well medicines like afatinib work in these people. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/634648 | ISSN: | 14796694 | DOI: | 10.2217/fon-2022-0842 |
顯示於: | 醫學院附設癌醫中心醫院(臺大癌醫) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。